- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- EXPERT BLOG: Provider status for pharmacists — one way or another
INDIANAPOLIS Lackluster results have prompted Eli Lilly to stop two late-stage clinical trials of a drug for treating Alzheimer’s disease, Lilly said Tuesday.
The drug maker said it would stop the phase-3 trials of semagacestat after preliminary results showed it did not slow the progression of the disease, while patients showed a worsening of cognitive functioning and the ability to perform daily activities.
Lilly said it still was investigating the monoclonal antibody solanezumab as a treatment for Alzheimer’s disease in another phase-3 trial.